Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Leadiant Biosciences Inc.

Division of Sigma-Tau Finanziaria SPA
leadiant.com

Latest From Leadiant Biosciences Inc.

EU Regulatory System Attacked Over Quality Of Approvals

If anyone can throw cold water on the claimed benefits of some of Europe's most recently approved medicines, it’s the international drug bulletin, Prescrire. In an assessment of 108 of the pharma industry’s latest offerings, it gives a cautious welcome to some but says that more than half bring nothing new and others could even be dangerous to patients.

Europe Drug Approval Standards

Dutch Hospital Resumes Own Manufacture Of Leadiant’s Costly Drug

While the Dutch government negotiates an acceptable price for Leadiant Biosciences’ orphan drug CDCA, a university hospital has resumed supplying pharmacy compounded versions of the drug after addressing initial problems with the sourcing of raw materials.

Netherlands Manufacturing

Leadiant Hit By Second Complaint Over Price Of CTX Drug In Europe

A second complaint has been filed, this time in Belgium, over the “excessive” price hike on Leadiant’s CDCA-containing drug for the rare genetic disorder, CTX.

Belgium Netherlands

Japan Approvals Include World-First For Skyrizi, Kymriah As Asia's First CAR-T

Japan approves a large batch of new products including significant first nods globally for AbbVie's antibody for psoriasis and Japan's first gene-based therapy, as well as a pioneering first approval in Asia for a CAR-T drug.

Japan Approvals
See All

Company Information

  • Industry
  • Pharmaceuticals
    • OTC, Consumer
  • Therapeutic Areas
  • Cancer
  • Gastrointestinal
  • Gynecological, Urological
  • Immune Disorders
  • Infectious & Viral Diseases
  • Ophthalmic
  • Renal System
  • Alias(es)
  • Sigma-Tau Pharmaceuticals Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Sigma-Tau Finanziaria SPA
  • Senior Management
  • Michael Minarich, CEO
    Giuseppe Izzi, VP, Fin.
    Taha Keilani, MD, VP, CMO
  • Contact Info
  • Leadiant Biosciences Inc.
    Phone: (301) 948-1041
    9841 Washingtonian Blvd.
    Ste. 500
    Gaithersburg, MD 20878
    USA
UsernamePublicRestriction

Register